Fig. 5. Octet BLI competition assay using D25 and motavizumab.

Slides:

Advertisements

Similar presentations

Fig. 1 CSF1 is increased in blood of melanoma patients and correlates with disease progression. CSF1 is increased in blood of melanoma patients and correlates.

Advertisements

Competition binding assays.

Fig. 5. Correlation of tail and long bone growth velocities with Cxm serum concentrations in mice. Correlation of tail and long bone growth velocities.

Fig. 6 ROC curves of mCCNA1 and mVIM assayed on esophageal balloon samplings of the distal esophagus. ROC curves of mCCNA1 and mVIM assayed on esophageal.

Fig. 1. In vitro binding and neutralization activities of C12G6.

Fig. 4. The effect of single-dose rozanolixizumab on the concentration of IgG subtypes in healthy subjects. The effect of single-dose rozanolixizumab on.

Fig. 5. Prophylactic and therapeutic efficacy of C12G6 in ferrets.

Fig. 7 Vaccine-induced influenza-specific B cells are not maintained in peripheral blood. Vaccine-induced influenza-specific B cells are not maintained.

Fig. 5. Rises in RSV PRNT during the surveillance period.

Fig. 6 Transmissibility of adiposity from humanized mice to germ-free recipients. Transmissibility of adiposity from humanized mice to germ-free recipients.

Fig. 7 Correlation of NHP and human ISGs.

Fig. 3. The effect of VRC01 infusion on virus load in plasma and blood CD4 T cells during ART. The effect of VRC01 infusion on virus load in plasma and.

Consolidated Standards of Reporting Trials flow diagram of VRC trial

Fig. 2 Whisker deprivation accelerates and enhances behavioral recovery after right S1FP photothrombosis. Whisker deprivation accelerates and enhances.

Fig. 2 AcPGP induces IL-8 and G-CSF release from human bronchial epithelial cells. AcPGP induces IL-8 and G-CSF release from human bronchial epithelial.

Fig. 2. Clinically actionable somatic genomic alterations in various tumor types. Clinically actionable somatic genomic alterations in various tumor types.

Fig. 5. Microarray analysis of tumors treated by dabrafenib, trametinib, or the combination of dabrafenib and trametinib with pmel-1 ACT or mock ACT. Microarray.

Fig. 1. Schematic showing the shedding of tumor DNA from head and neck cancers into the saliva or plasma. Schematic showing the shedding of tumor DNA from.

Fig. 3. Comparison of prediction performance.

Fig. 6. TIV-09, but not MIV-09, induces an IFN signature in the blood of vaccinated individuals at day 1. TIV-09, but not MIV-09, induces an IFN signature.

Fig. 3 ROC curves of mCCNA1 and mVIM assayed in esophageal cytology brushings from control normal-appearing GE junctions versus BE and EAC cases. ROC curves.

Fig. 4. The effect of combined inhibition of BCL-2 and BCR-ABL on leukemia LT-HSC frequency. The effect of combined inhibition of BCL-2 and BCR-ABL on.

Fig. 2 Preserved long-term functionality of the TEHVs over 1-year follow-up as assessed by ICE and cardiac MRI flow measurements. Preserved long-term functionality.

In vivo release of doxycycline hyclate from the GRS in a swine model

Fig. 2. Deficiency of neuronal HS leads to reduced neuroinflammation.

Fig. 5 Cell-free membrane cyclase assay confirms that candidate compounds are specific antagonists of hNPR1. Cell-free membrane cyclase assay confirms.

Fig. 2. Bacterial/viral score in COCONUT-conormalized whole-blood validation data sets. Bacterial/viral score in COCONUT-conormalized whole-blood validation.

Colonization in tumor models and different modes of administration

Fig. 5. Vitamin B12 supplementation in the host altered the transcriptome of P. acnes in the skin microbiota. Vitamin B12 supplementation in the host altered.

Fig. 4 Device accuracy results (n = 32 users).

Fig. 3. Increased expression of exhaustion markers and apoptosis markers on CAR8 cells in the presence of TCR antigen. Increased expression of exhaustion.

Fig. 1 BMS binds to the pseudokinase domain of TYK2 and inhibits receptor-mediated TYK2 activation and downstream phosphorylation events in human.

Fig. 4 Administration of BMS to mice inhibits autoimmune-relevant pharmacodynamic endpoints driven by IL-12 and IFNα. Administration of BMS

Fig. 3 BMS blocks functional responses in primary immune cells driven by IL-23 and IL-12. BMS blocks functional responses in primary immune.

BMS blocks functional responses in primary immune cells driven by IFNα

Fig. 1. Detection of circulating tumor DNA in CRPC patients.

The microchip-based drug delivery device and overview of study design

Fig. 1. A model to explain the pleiotropy of CEP290 disease.

Fig. 5. miR p inhibits the translational initiation of CACNA1A IRES–driven α1ACT by eIF4AII and eIF4GII. miR p inhibits the translational initiation.

Fig. 2 PK dosing results. PK dosing results. (A) Plasma concentration of hPTH(1–34) versus time after release of 40-μg dose from implanted microchip device.

Fig. 3. In vivo tumor responses are mechanism of action–specific and concentration-dependent. In vivo tumor responses are mechanism of action–specific.

Fig. 3 Local Maraba treatment of TNBC tumors provides long-term systemic protection. Local Maraba treatment of TNBC tumors provides long-term systemic.

Fig. 1 Most models of biological responses to climate change omit important biological mechanisms. Most models of biological responses to climate change.

Fig. 1 Crohn’s disease association within the LRRK2 locus.

Fig. 6 Multivalent DNA vaccine and protein antigen delivery by T4-AAV nanoparticles. Multivalent DNA vaccine and protein antigen delivery by T4-AAV nanoparticles.

Fig. 2 Effect of CSF sTREM2– and CSF sTREM2–to–p-tau181 ratio on changes in cognition. Effect of CSF sTREM2– and CSF sTREM2–to–p-tau181 ratio on changes.

Fig. 2 Isopropanol-tolerant E. faecium resists disinfection.

Fig. 8. Purkinje cell quantification and hearing threshold in NPC cats administered IC HPβCD. Purkinje cell quantification and hearing threshold in NPC.

Fig. 5. Vascularization of human liver seed grafts.

Fig. 2. Overexpression of miR cluster in the developing heart results in increased cardiomyocyte proliferation and cardiomegaly. Overexpression.

Fig. 3 Mmp-2−/− mice are protected from obesity and leptin resistance.

by Peter Bacchetti, Steven G. Deeks, and Joseph M. McCune

Binding characteristics of mAbs isolated from plasmablasts during acute ZIKV infection. Binding characteristics of mAbs isolated from plasmablasts during.

Fig. 4. miR promotes cardiomyocyte proliferation through regulation of Hippo pathway kinases. miR promotes cardiomyocyte proliferation through.

Fig. 5. High burdens of AA signature mutations and predicted immunogenicity in Taiwan HCCs. High burdens of AA signature mutations and predicted immunogenicity.

Effects of highly concentrated SFN provided as BSE in T2D patients

Fig. 1 ZMAb improves survival of EBOV-challenged NHPs

Fig. 7 BEL immune response.

Fig. 3. miR overexpression leads to increased cell proliferation as well as altered differentiation and metabolism in cardiomyocytes. miR

Fig. 3. Association between peak CTL019 expansion and response.

Fig. 1. APP/PS1;C3 KO mice show improved cognitive flexibility (reversal) compared to APP/PS1 mice at 16 months of age. APP/PS1;C3 KO mice show improved.

Fig. 5. SUS treatment reduces Aβ in a second cohort of AD mice.

Fig. 1. Schematic description of whole-exome or targeted next-generation sequencing analyses. Schematic description of whole-exome or targeted next-generation.

Fig. 4 Gallium increases P. aeruginosa sensitivity to peroxides.

Fig. 8 Immune correlates of protection.

Fig. 3 Postnatal assembly of the humanized gut microbiota.

Fig. 2. Cellular response to FolamiRs in vitro.

Fig. 1 Anti-LtxA antibody concentrations in various patient groups.

Fig. 6. Connectivity and mobility maps for Lesotho.

Fig. 1. Maps of Lesotho, a landlocked country within South Africa.

Presentation transcript:

Fig. 5. Octet BLI competition assay using D25 and motavizumab. Octet BLI competition assay using D25 and motavizumab. (A) In a BLI assay, biosensor tips were dipped in pre-F, then into analyte, and then into competing antibody. D25 does not inhibit motavizumab binding to pre-F and vice versa, making these mAbs eligible for use in serum analysis. (B) Biosensor tips were dipped into pre-F, then into D25 or motavizumab, and then into sera. The mean percent inhibition of serum antibody binding by D25 is ~40%, and that by motavizumab is ~60%. Unlike motavizumab, there is increasing inhibition by D25 with increasing NT titers. The dashed line represents background binding inhibition. (C) A moderate correlation is found between percent binding inhibited by D25 and reciprocal EC50 NT titers, and a weak inverse correlation was found between percent binding blocked by motavizumab and NT titers. Joan O. Ngwuta et al., Sci Transl Med 2015;7:309ra162 Copyright © 2015, American Association for the Advancement of Science